Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. (a foreign private issuer) on January 29, 2018. The filing incorporates by reference a press release dated January 29, 2018, announcing a capital raising event. The registrant is based in Kfar Saba, Israel.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, or existing debt levels. The primary financial metric disclosed is the size of a new financing round:
- Registered Direct Offering: $4 million.
Material Changes
The material change reported is the execution of a $4 million registered direct offering. This represents a significant liquidity event for the company, though the filing does not detail the impact on prior period financials or specific use of proceeds beyond the announcement of the transaction.
Guidance, Outlook, and Risks
The filing does not contain management commentary regarding future guidance, operational outlook, or specific risk factors. The document serves primarily to disclose the press release regarding the capital raise. No unusual items or contingencies are described in the provided text.
Investor Verification Checklist
- Verify the final closing status and actual proceeds received from the $4 million registered direct offering.
- Confirm the specific terms of the offering, including the purchase price per share and any warrants or options issued.
- Review the company's latest audited financial statements (Form 20-F) to assess current cash runway and burn rate, as this filing does not provide those figures.
- Identify the lead investor(s) participating in the registered direct offering.